Picture of Mineralys Therapeutics logo

MLYS — Mineralys Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSucker Stock

Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Mineralys Therapeutics Inc  MLYS.OQ  reported a quarterly
adjusted loss of $1.13​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -57 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 83 cents per
share. Wall Street expected results to range from -93 cents
to -66 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Mineralys Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.13​.
    * The company reported a quarterly loss of $56.34 million.
    * Mineralys Therapeutics Inc shares had risen by 15.9% this
quarter and gained 63.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Mineralys
Therapeutics Inc is 31.00 
This summary was machine generated from LSEG data November 12 at
03:42 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.83          -1.13          Missed
 Mar. 31 2024      -0.70          -0.83          Missed
 Mar. 31 2024      -0.67          -0.70          Missed
 Dec. 31 2023      -0.82          -0.61          Beat

Recent news on Mineralys Therapeutics

See all news